Literature DB >> 23065536

Converging technologies: a critical analysis of cognitive enhancement for public policy application.

Christos Makridis1.   

Abstract

This paper investigates cognitive enhancement, specifically biological cognitive enhancement (BCE), as a converging technology, and its implications for public policy. With an increasing rate of technological advancements, the legal, social, and economic frameworks lag behind the scientific advancements that they support. This lag poses significant challenges for policymakers if it is not dealt with sufficiently within the right analytical context. Therefore, the driving question behind this paper is, "What contingencies inform the advancement of biological cognitive enhancement, and what would society look like under this set of assumptions?" The paper is divided into five components: (1) defining the current policy context for BCEs, (2) analyzing the current social and economic outcomes to BCEs, (3) investigating the context of cost-benefit arguments in relation to BCEs, (4) proposing an analytical model for evaluating contingencies for BCE development, and (5) evaluating a simulated policy, social, technological, and economic context given the contingencies. In order to manage the risk and uncertainty inherent in technological change, BCEs' drivers must be scrutinized and evaluated.

Mesh:

Substances:

Year:  2012        PMID: 23065536     DOI: 10.1007/s11948-012-9396-1

Source DB:  PubMed          Journal:  Sci Eng Ethics        ISSN: 1353-3452            Impact factor:   3.525


  28 in total

1.  Science's new social contract with society.

Authors:  M Gibbons
Journal:  Nature       Date:  1999-12-02       Impact factor: 49.962

2.  Off-label uses of modafinil.

Authors:  E Teitelman
Journal:  Am J Psychiatry       Date:  2001-08       Impact factor: 18.112

3.  Facilitation of implicit motor learning by weak transcranial direct current stimulation of the primary motor cortex in the human.

Authors:  Michael A Nitsche; Astrid Schauenburg; Nicolas Lang; David Liebetanz; Cornelia Exner; Walter Paulus; Frithjof Tergau
Journal:  J Cogn Neurosci       Date:  2003-05-15       Impact factor: 3.225

4.  Ongoing adaptive evolution of ASPM, a brain size determinant in Homo sapiens.

Authors:  Nitzan Mekel-Bobrov; Sandra L Gilbert; Patrick D Evans; Eric J Vallender; Jeffrey R Anderson; Richard R Hudson; Sarah A Tishkoff; Bruce T Lahn
Journal:  Science       Date:  2005-09-09       Impact factor: 47.728

5.  Why neuroscience business development?

Authors:  Alan M Zuckerman; Christine H Markham
Journal:  Healthc Financ Manage       Date:  2006-06

6.  Cognitive enhancement: methods, ethics, regulatory challenges.

Authors:  Nick Bostrom; Anders Sandberg
Journal:  Sci Eng Ethics       Date:  2009-06-19       Impact factor: 3.525

7.  Emerging and continuing trends in vaccine opposition website content.

Authors:  Sandra J Bean
Journal:  Vaccine       Date:  2011-01-14       Impact factor: 3.641

Review 8.  Modafinil: preclinical, clinical, and post-marketing surveillance--a review of abuse liability issues.

Authors:  Hugh Myrick; Robert Malcolm; Brent Taylor; Steven LaRowe
Journal:  Ann Clin Psychiatry       Date:  2004 Apr-Jun       Impact factor: 1.567

9.  Augmentation of exposure therapy with D-cycloserine for social anxiety disorder.

Authors:  Stefan G Hofmann; Alicia E Meuret; Jasper A J Smits; Naomi M Simon; Mark H Pollack; Katherine Eisenmenger; Michael Shiekh; Michael W Otto
Journal:  Arch Gen Psychiatry       Date:  2006-03

10.  Navigating a research partnership between academia and industry to assess the impact of personalized genetic testing.

Authors:  Lisa Soleymani Lehmann; David J Kaufman; Richard R Sharp; Tanya A Moreno; Joanna L Mountain; J Scott Roberts; Robert C Green
Journal:  Genet Med       Date:  2012-01-12       Impact factor: 8.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.